Neonatal lupus erythematosus: studies on HLA class II genes and autoantibody profiles in Japanese mothers.
Neonatal lupus erythematosus (NLE) is a rare disorder of neonates characterized by two major clinical manifestations: congenital heart block and cutaneous lupus lesions. The disease is associated with placentally transferred maternal anti-Ro/SSA and/or La/SSB antibodies. To clarify possible class II HLA associations with maternal autoantibody responses, haplotypic and allelic distributions, along with the polymorphism of the MHC class II HLA alleles, were analyzed based on PCR-RFLP results in 25 Japanese mothers of two groups defined by precipitating autoantibody profiles. Among mothers with both anti-Ro/SSA and anti-La/SSB antibodies, but not those with anti-Ro/SSA alone, the class II haplotypes DRB1*1101-DQA1*0501-DQB1*0301 and DRB1*08032-DQA1*0103-DQB1*0601 as well as individual class II alleles DRB1*1101, DRB1*08032 and DQB1*0301 showed significantly increased frequencies compared to those in normal controls. All anti-Ro/SSA and anti-La/SSB positive mothers carried DRB1 alleles that shared the same amino acid residues at positions 14-31 and 71 of the DRB1 chain. These mothers also carried homozygous or heterozygous DQ6 and DQ3 alleles that shared the same amino acid residues at positions 27-36 and 71-77 of hypervariable regions of the DQB1 chain. Furthermore, all mothers with both anti-Ro/SSA and anti-La/SSB were homozygous for DPB1*0501. Nine of 10 anti-Ro/SSA and anti-La/SSB-positive mothers, but only 6 of 15 mothers with anti-Ro/SSA alone, had affected infants. Thus, our findings suggest that there may be immunogenetic differences among mothers according to their autoantibody profiles, and that mothers with both anti-Ro/SSA and anti-La/SSB are more likely to have infants with NLE than mothers with anti-Ro/SSA alone.
Miyagawa
S
S
Department of Dermatology, Nara Medical University, Kashihara City, Japan.
Shinohara
K
K
Kidoguchi
K
K
Fujita
T
T
Fukumoto
T
T
Hashimoto
K
K
Yoshioka
A
A
Shirai
T
T
D000818:Animals; D000974:Antibodies, Antinuclear / Q000032:analysis; D001323:Autoantibodies / Q000145:classification*; D004247:DNA / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005787:Gene Frequency; D005802:Genes, MHC Class II / Q000235:genetics* / Q000276:immunology; D005838:Genotype; D006683:HLA-DQ Antigens / Q000737:chemistry / Q000235:genetics; D006684:HLA-DR Antigens / Q000737:chemistry / Q000235:genetics; D006239:Haplotypes; D006327:Heart Block / Q000151:congenital; D006801:Humans; D007231:Infant, Newborn; D007564:Japan; D008178:Lupus Erythematosus, Cutaneous / Q000235:genetics / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000235:genetics / Q000276:immunology*; D009035:Mothers; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D011817:Rabbits; D012859:Sjogren's Syndrome / Q000276:immunology
D000974:Antibodies, Antinuclear; D001323:Autoantibodies; D006683:HLA-DQ Antigens; D006684:HLA-DR Antigens; C035356:SS-A antibodies; C035357:SS-B antibodies; D004247:DNA